19:20 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Schizophrenia; depression Cell culture studies suggest inhibiting DISC1-FBXW7 binding could help treat schizophrenia and major depressive disorder (MDD). In human neuroprogenitor cells (NPCs) differentiated from induced pluripotent stem (iPS) cells generated from skin samples of...
20:39 , Jul 20, 2017 |  BC Extra  |  Preclinical News

FBXW7-DISC1 complex linked to schizophrenia

In a paper, researchers showed that F-box and WD repeat domain containing 7 (FBXW7; FBW7) controls levels of a scaffold protein, disrupted in schizophrenia 1 (DISC1), which is deficient in hereditary schizophrenia. The research suggests...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
07:00 , Mar 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Myeloid leukemia cell differentiation protein (MCL1); f-box and WD repeat domain containing...
07:00 , Mar 17, 2011 |  BC Innovations  |  Targets & Mechanisms

MCL1's resistance story

Separate studies by Harvard Medical School and Roche's Genentech Inc. unithave shown that increased levels of myeloid leukemia cell differentiation protein, an antiapoptotic protein in the B cell lymphoma 2 family, can enable acute lymphoblastic...
07:00 , Jul 29, 2010 |  BC Innovations  |  Targets & Mechanisms

Inhibiting E3 ligases

Separate groups of researchers have identified highly selective small molecule inhibitors of E3 ubiquitin ligase,1,2 a large multi-subunit complex involved in protein degradation that has been considered difficult, if not impossible, to target. The compounds...
07:00 , Jul 15, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer F-box and WD repeat domain containing 7 (FBXW7; FBW7) An allosteric inhibitor of FBXW7, a subunit...
07:00 , Sep 25, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer ...
07:00 , Jul 31, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Target/marker /pathway Summary Licensing status Publication and contact information Cancer Nucleophosmin (nucleolar phosphoprotein...